PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: General Electric Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Capital Provides $11.25 Million Credit Facility to Pacira Pharmaceuticals, Inc. - GE Capital, Healthcare Financial Services today announced it has provided an $11.25 million credit facility to Pacira Pharmaceuticals, Inc. (NYSE: GE)
GE Capital Provides $11.25 Million Credit Facility to Pacira Pharmaceuticals, Inc.

 

NewswireToday - /newswire/ - Bethesda, MD, United States, 2010/05/11 - GE Capital, Healthcare Financial Services today announced it has provided an $11.25 million credit facility to Pacira Pharmaceuticals, Inc. (NYSE: GE). NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The financing provides working capital, and facilitates advances toward regulatory approval and preparation for commercialization of Pacira’s EXPAREL™ program.

Based in San Diego, CA, Pacira is an acute care specialty pharmaceutical company with a primary focus on formulating, developing and manufacturing sustained-release, injectable products. EXPAREL™ is the company’s bupivacaine-based product administrated by wound infiltration that is designed to deliver extended relief of postoperative pain. Pacira announced positive results for two separate Phase III placebo controlled EXPAREL™ studies in Q4 2009.

"GE’s industry knowledge and financing experience were instrumental in structuring this transaction," said James S. Scibetta, chief financial officer of Pacira Pharmaceuticals, Inc. “This new facility will help us invest in our existing businesses and support further advancement of what we believe will be an important postoperative pain product.”

“We are pleased to provide capital to Pacira as they work to advance toward regulatory approval and commercialization of the EXPAREL™ product,” said Anthony Storino, senior managing director for GE Capital, Healthcare Financial Services’ life science finance group. “GE’s healthcare expertise and financing experience provide our customers the resources they need to support critical business objectives, including advancements in vital healthcare products.”

About GE Capital, Healthcare Financial Services
With over $17 billion invested, GE Capital, Healthcare Financial Services is a premier provider of capital and services to the healthcare industry, with investments in more than 30 sub-sectors including senior housing, hospitals, pharmaceuticals, and medical devices. Our team of professionals provides deep industry expertise to create business and financial solutions tailored to meet the individual needs of our customers. The Life Science Finance team has worked with more than 500 companies throughout the United States, Canada and Europe. With a dedicated focus on assisting life science companies large and small, from the first venture round to post-IPO, the team has provided over $2.5 billion in financing to the market. For more information, visit gecapital.com/healthcare/.

GE Capital offers consumers and businesses around the globe an array of financial products and services. For more information, visit gecapital.com or follow company news via Twitter (@GECapital). GE (ge.com) is a diversified infrastructure, finance and media company taking on the world’s toughest challenges.

About Pacira
Pacira Pharmaceuticals, Inc. (pacira.com) is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care market. The company's most advanced product is EXPAREL™ (DepoBupivacaine), a bupivacaine-based product intended to deliver postoperative pain relief by infiltration. In Q4 2009, Pacira announced positive results for two separate Phase III placebo controlled EXPAREL™ studies. EXPAREL™ benefits from the proprietary DepoFoam® Technology owned by Pacira. Two other DepoFoam®-based products -- DepoDur® and DepoCyt/DepoCyte® are marketed by partners in several global territories. The DepoFoam® technology also forms the basis of multiple development projects providing Pacira an opportunity to expand its pipeline. Pacira owns two cGMP production facilities which produce the two approved products, EXPAREL™ clinical development and all pipeline materials.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Capital Provides $11.25 Million Credit Facility to Pacira Pharmaceuticals, Inc.

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GE News Center |
Publisher Contact: Ned Reynolds - GE Capital Americas 
203-229-5717 ned.reynolds[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry
Therapist Launches Podcast to Reach Larger Audience
Top Innovative Health and Wellness Technologies to Accelerate Global Adoption of Precision Medicine Finds Frost & Sullivan
Rheumatoid Arthritis Diagnosis Tests Market Size to Expand At 6.2% CAGR through 2022 Says PMR
Persistence Market Research Publishes Health Information Exchange Market Opportunities and Forecasts 2017-2025
Persistence Market Research Publishes Microtome Cryostat Equipment Market Opportunities and Forecasts, 2017-2025
North America to Account for 4.3% CAGR in Global Hip Replacement Market Reports Persistence Market Research
HPMC Capsules Market to Register 10.9% CAGR During 2017-2025 Finds Persistence Market Research
Persistence Market Research Publishes Blood Thinner Market Opportunities and Forecasts 2017-2025
Occupational Medicine Market Estimated to Expand At A Robust CAGR Over 2025 Notes PMR
Persistence Market Research Publishes Traditional Chinese Medicine Market Forecast Over 2017-2025
Inferior Vena Cava Filters Market to Register A Strong Growth by 2025 Notes Persistence Market Research
Plasma Component Separator Market Set to Surge Significantly During 2017-2025 Says PMR
Persistence Market Research Releases Fertility Enhancing Treatment Market Snapshot by 2017-2025
Disposable Diabetes Devices Market Expected to Generate Huge Profits by 2025 Finds Reports Persistence Market Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)